{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Antigen[C268]" in comments (approximate match)
Status:
US Approved Rx
(1971)
First approved in 1971
Source:
BLA101069
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1998)
First approved in 1970
Source:
BLA103821
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1999)
First approved in 1953
Source:
BLA103915
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
INFLUENZA VIRUS VACCINE, H5N1 by SANOFI PASTEUR INC
(2007)
Source URL:
First approved in 2007
Source:
INFLUENZA VIRUS VACCINE, H5N1 by SANOFI PASTEUR INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
INFLUENZA VIRUS VACCINE, H5N1 by SANOFI PASTEUR INC
(2007)
Source URL:
First approved in 2007
Source:
INFLUENZA VIRUS VACCINE, H5N1 by SANOFI PASTEUR INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
PLAGUE VACCINE by GREER LABORATORIES INC
(1994)
Source URL:
First approved in 1994
Source:
PLAGUE VACCINE by GREER LABORATORIES INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02542462: Phase 4 Interventional Completed Intussusception
(2015)
Source URL:
First approved in 2006
Source:
BLA125122
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02542462: Phase 4 Interventional Completed Intussusception
(2015)
Source URL:
First approved in 2006
Source:
BLA125122
Source URL:
Class:
STRUCTURALLY DIVERSE